Advanced searches left 3/3

Cardiac Amyloidosis - DOAJ

Summarized by Plex Scholar
Last Updated: 05 December 2022

* If you want to update the article please login/register

Transcatheter aortic valve replacement in aortic stenosis and cardiac amyloidosis: a systematic review and meta‐analysis

CA has a concomitant diagnosis of a significant older adults with severe AS related to transcatheter aortic valve replacement. We've long been doubted, but we want to present a complete review of the effectiveness and safety of TAVR in CA patients, as well as newly published results. Methods and findings We conducted a systematic review and meta-analysis of studies comparing mortality with TAVR in CA patients and reporting challenges and health outcomes of TAVR in CA patients with compared to patients with AS alone, as well as patients with TAVR in CA,u2010AS patients.

Source link: https://doi.org/10.1002/ehf2.13876


Two‐year outcome of ventricular assist device via a modified left atrium to aorta approach in cardiac amyloidosis

Patients with the LVAD in a small left ventricle are unlikely to be referred to these patients due to high perioperative risks and dangers of suction events. We report the 2 year end result and discuss the challenges faced in the care of our patients with end-stage heart disease due to cardiac amyloidosis, who was successfully treated with an LVAD using a modified left atrium to aorta implantation method.

Source link: https://doi.org/10.1002/ehf2.14039


Electrical cardioversion of atrial arrhythmias with cardiac amyloidosis in the era of direct oral anticogulants

Aims Atrial fibrillation/atrial flutter is common during cardiac amyloidosis. LAT is a common symptom in CA patients with AF/atrial flutter. In California patients receiving EC, most commonly treated with direct oral anticoagulants, we set out to determine EC characteristics, LAT prevalence, and risk factors, as well as AF/atrial flutter outcomes. Methods and findings This research included all patients with CA and AF/atrial flutter for the first time as a member of the national referral center for amyloidosis for EC from June 2017 to February 2021. In only 17% of cases, complete thrombus resolution was observed. The EC acute success rate was 88%, and we observed no complications after EC. Following a mean follow-up of 30 % to 27 months, a result of 64% among patients under amiodarone was 51%. Conclusions Left atrial thrombus was found in 14% of CA patients enrolled for EC and mainly treated with DOAC, and mainly treated with DOAC.

Source link: https://doi.org/10.1002/ehf2.14082


Incidence and predictors of worsening heart failure in patients with wild‐type transthyretin cardiac amyloidosis

Methods From September 2017 to February 2021, 104 patients with ATTRwt were diagnosed and prospectively followed from the time of diagnosis to death or the censorship date of 1 February 2021. At least twice, seventy-u2010three percent of patients with WHF were admitted at least twice. Patients with WHF during the first year had significantly reduced longevity. During the follow-up to WHF, independent predictors of WHF were pacemaker implantation prior to diagnosis and right atrial volume index. Patients with PMI had a higher left ventricular mass index and poorer left ventricular and right ventricular systolic function, indicating a more advanced stage of amyloid disease. Conclusions and Conclusions In younger patients with ATTRwt, which was related to reduced survival, a high incidence and recurrence of hospital admissions with WHF were observed. Patients with pacemaker systems prior to ATTRwt's diagnosis had more frequent hospitalizations with WHF.

Source link: https://doi.org/10.1002/ehf2.14000


Transthyretin Cardiac Amyloidosis Mimicking Immune Checkpoint-Induced Myocarditis in a Patient Treated with Atezolizumab and Bevacizumab for Advanced Hepatocellular Carcinoma: A Case Report

Advanced hepatocellular carcinoma can be treated with a combination of atezolizumab and bevacizumab. Magnetic resonance imaging of transthyretin cardiac amyloidosis may lead to mistrust of transthyretin cardiac amyloidosis, according to technetium pyrophosphate bone scintigraphy.

Source link: https://doi.org/10.1159/000526534


A Machine Learning Challenge: Detection of Cardiac Amyloidosis Based on Bi-Atrial and Right Ventricular Strain and Cardiac Function

This research challenges state-of-the-art cardiac amyloidosis diagnostics by injecting multi-chamber strain and cardiac function into supervised machine learning algorithms. Methods: Cardiovascular magnetic resonance imaging was performed in Forty-three California, 20 patients with hypertrophic cardiomyopathy, and 44 healthy controls. The decision tree's 41-feature matrix for decision tree, left atrial, right atrial, and cardiac function was developed by the same code as the SVM linear and SVM radial basis function kernel algorithm processing, according to a 41-feature matrix. Machine learning of multi-chamber cardiac strain and function may provide novel insights for non-contrast clinical decision-support methods in CA diagnostics.

Source link: https://doi.org/10.3390/diagnostics12112693


Evolving trends in epidemiology and natural history of cardiac amyloidosis: 30-year experience from a tertiary referral center for cardiomyopathies

ObjectivesAbouteachment is unclear amyloidosis's natural history is unclear. Preferred patients in the u201cTrieste CA Registry from January 1, 1990 to December 31, 2021 were divided into a historical cohort and a contemporary cohort, with each varying mortality of various types of CA over a 30-year period. The number of patients with AL and ATTR-CA has gradually increased over time, with most ATTR-CA patients treated non-invasively. In comparison to the early rise in mortality in AL-CA, a more sustained rise in event-rate was observed in the long run in ATTR-CA. paraphrasedoutput:ConclusionAndRegency. com's main aim was a multivariable analysis, ATTR-CA, eGFR, and ACE-inhibitor therapy predicted overall survival in the contemporary cohort, with notable rises in the 2-year survival of ATTR-CA patients from the new cohort.

Source link: https://doi.org/10.3389/fcvm.2022.1026440

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions